On a federal level, LSD is considered an illicit substance without accepted medical utility, and was prohibited in 1968 (Das et al., 2016). Nowadays, the number of users continues to be relatively small; epidemiological data shows that recreational use varies depending on specific populations: around 0.2% of people aged 12 or older report using this drug within the past month, and 0.8% report use at least once in a 12-month period of time (Hart & Ksir, 2022).

As of early 2026, psilocybin is still classified by the United States government as a Schedule I drug (Alcohol and Drug Foundation, 2025). This means that legally it is considered to have a high potential for abuse, no accepted medical use, and to be dangerous to use. One study found that in 2013 there were 21 million people who reported using psilocybin in their lifetime, with young adults around 20-25 being the most prevalent users (Krebs & Johansen, 2013).

The main way of administration of LSD is through oral ingestion since it has a rapid absorption from the gastrointestinal tract (Hart & Ksir, 2022). Since a minimal amount of LSD is needed to produce intense psychoactive effects, liquid LSD is usually applied to a specialized paper that is divided into tabs instead of consuming it directly. Once this drug is consumed, it goes through the bloodstream; however, it does not target the brain selectively. The maximal concentration in the blood is reached at around 90 minutes, marking a typical peak of the onset (Hart & Ksir, 2022).

In addition, LSD has a rapid hepatic clearance with a short plasma elimination half-life of around 3 hours (Hart & Ksir, 2022). The liver metabolizes this drug, transforming it into a completely inactive compound (2-oxy-lysergic acid diethylamide) before excretion (Hart & Ksir, 2022). However, psychological effects persist significantly longer than its half-life suggests. Daily consumption alters pharmacodynamics, making users develop tolerance rapidly in just a matter of 3 or 4 days. This generates cross-tolerance with other psychedelics like mescaline, even though clinical evidence shows physical dependence does not happen (Hart & Ksir, 2022).

Psilocybin is usually consumed by orally ingesting the mushrooms which contain the chemical. The mushrooms can be eaten fresh, dry, cooked, or brewed into a tea. The effects of psilocybin tend to kick in about 30 minutes when eaten, but they kick in much quicker when brewed in tea. Some report onset within 5-10 minutes when drunk as a tea. After the symptoms onset, the effects will last about four to six hours, with most people reporting the peak around the 2nd hour (Alcohol and Drug Foundation, 2025). The amount that is taken also affects the level of inebriation, with larger doses leading to more intense effects (Smausz et al., 2022).

LSD significantly alters central nervous system communication, affecting specifically the prefrontal cortex. Under the effects of this drug, resting fMRI analyses show a deep transformation in neural systems, having a positive impact by producing stronger interregional connectivity and reduced self-inhibition across the brain (Bedford et al., 2023). LSD’s effects on the prefrontal cortex cause behavioral consequences like distorted thinking speed, impaired ability to concentrate, and induced ego-dissolution. The disruption of the normal sensory gating networks underlies alterations in time perception, concentration, and cognitive processing that are observed during consumption (Bedford et al., 2023).

At a neurochemical level, LSD acts as a potent agonist at the serotonin receptor site, and when binding to these receptors, LSD mimics serotonin and activates pathways that differ from catechol psychedelics, setting off the psychological and physiological symptoms of a classical psychedelic experience (Das et al., 2016). This agonist binding triggers a downstream effect on neural communication by mediating prefrontal cortical excitatory synaptic currents, resulting in cellular excitation that disrupts normal inhibitory feedback loops, causing a reduction in regional self-inhibition and an increase in whole-brain connectivity (Das et al., 2016; Bedford et al., 2023).

There is significant evidence that psilocybin affects the default-mode network (DMN), primarily the prefrontal cortex and hippocampus. This likely helps to explain the acute cognition-, perception-, and emotion-altering properties of psilocybin. The DMN is densely connected with neurons and contains essential parts of the brain like the prefrontal cortex, which is primarily responsible for executive function, attention, and decision-making, as well as the hippocampus, which is the main structure involved in declarative memory processing. During the trip, parts of the DMN become less connected in their usual patterns, and more flexible and unusual neural pathways are visible in neural imaging. Even weeks after acute use, some brain regions showed subtle changes in connectivity. Participants also reported positive shifts in mood, attitudes, and outlook, suggesting psilocybin may leave lasting benefits (Smausz et al., 2022). Research on repetitive chronic use is unclear, but it appears that some rewiring shows up on fMRI in multiple brain regions (Subramanian et al., 2025).

Once psilocybin enters the body, it is processed into psilocin, which is chemically similar in shape to the neurotransmitter serotonin. Psilocin most commonly affects 5-HT receptors as a partial serotonin agonist. So, the effects of psilocybin are a result of it simulating serotonin and stimulating its receptors. It is also theorized that it has a profound effect on GABA, allowing for excessive excitation (Smausz et al., 2022).

LSD produces alterations in mood, perception, and cognition; users report intense visual distortions, time distortions, and a heightened appreciation of the environment (Hart & Ksir, 2022). Controlled trials using psychometric frameworks like the 5D-ASC scale demonstrate that these alterations manifest as cross-modal synesthesia and altered color/auditory perception (Li et al., 2022). The intensity of the subjective effects depends on the administered dose and varies among different individuals; moderate doses produce teeth grinding and lack of appetite, while higher doses magnify unfavorable reactions like paranoia (Hart & Ksir, 2022).

Psilocybin is a powerful psychedelic drug, which means it can affect all the senses, altering a person’s thinking, sense of time, and emotions. Though it can affect individuals differently based on brain chemistry, dosage, size of the user, tolerance, expectations, and environment, some commonly reported effects of the drug are a sense of euphoria, changes in consciousness and perception (colloquially referred to as a trip), dilated pupils, and visual or auditory hallucinations. The larger the dose consumed, the more intense these effects may appear (Alcohol and Drug Foundation, 2025).

At a physiological level, LSD works primarily as a sympathomimetic agent, stimulating the sympathetic nervous system to alter regular somatic functions (Hart & Ksir, 2022). Some of the earliest and most common physiological symptoms after oral ingestion include prominent pupillary dilation (mydriasis), increased salivation, and reduced appetite (Hart & Ksir, 2022; Das et al., 2016).

For psilocybin, physiologically the body shows signs of excitation including pupil dilation, rapid heartbeat, and increased body temperature, as well as some other symptoms such as headaches, stomach upset, nausea, and sweating/chills. Some users report what is referred to as a “bad trip,” in which the user may experience scary or unpleasant hallucinations, anxiety, and paranoia. This, however, is far less reported, and research has not been conducted that definitively determines why this happens (Alcohol and Drug Foundation, 2025).

The psychological and physiological changes users of psilocybin experience will greatly affect their behavior, as their perception of the world around them is profoundly altered, and thus they may act illogically, impulsively, and with a lack of attention (Alcohol and Drug Foundation, 2025). Psilocybin affects the prefrontal cortex, which runs a lot of important processes required in responsible decision-making. This interruption of the prefrontal cortex can help explain the erratic, seemingly nonsensical behavior of someone who is using psilocybin. This impaired state of reality can lead one to cause harm to themselves and others by accident through impulsivity and poor decision-making. However, most people do not become angry or violent (though it can happen in rare cases of bad trips), and a sense of euphoria, happiness, or elevated mood is widely reported (Subramanian et al., 2025).

It was found in a study that measured a head-twitching response when mice were administered psychedelics repeatedly over 4 days that repeated exposure to psychedelics (the class of drug psilocybin falls into) induced a progressive reduction in the head-twitching response. The study also noted that a tolerance to the head-twitching could be noted 24 hours after the administration of a single dose (de la Fuente Revenga et al., 2022). Tolerance develops very rapidly to psychedelics with consistent use, but with time away from using the drugs, the tolerance may wane. Those who are experiencing tolerance may need a larger dose to feel the effects or may feel less effect or no effect at all. However, despite tolerance forming, there does not seem to be any withdrawal symptoms from psilocybin even after regular use; some users report a headache, but most are easily able to quit the drug (Alcohol and Drug Foundation, 2025).

The dangers of using LSD are related to short-term behavioral toxicity rather than to damage to body tissue or to a fatal overdose; short-term physical side effects are dilated pupils, raised body temperature, high blood pressure, and insomnia (Hart & Ksir, 2022; Li et al., 2022). There are no known human fatalities resulting from an absolute physiological overdose of LSD (Hart & Ksir, 2022). The main acute risks are behavioral panic reactions, also known as “bad trips,” which may lead to unintentional injuries or trauma; long-term effects include Hallucinogen Persisting Perception Disorder (HPPD), which occurs when users have visual flashbacks long after they have taken the drug (weeks or months) (Hart & Ksir, 2022). In addition, alcohol or other drugs may aggravate confusion of the mind and increase panic (Das et al., 2016).

It is rare for psilocybin use to produce life-threatening or fatal symptoms even when a large dose is consumed. However, when users take a large amount, they may experience side effects such as agitation, vomiting, paranoia, muscle weakness, psychosis, seizure, and, in rare cases, comas (Alcohol and Drug Foundation, 2025). This may be due to the drug acting as a serotonin agonist, as these symptoms closely align with the symptoms reported with elevated serotonin. It is also important not to mix psilocybin with other medications that affect serotonin, as they may interact (Smausz et al., 2022).

Clinical data indicates that LSD and other psychedelic substances have significant therapeutic potential, with medicinal benefits for a growing number of psychiatric and neurodegenerative illnesses such as depression, post-traumatic stress disorder (PTSD), and alcohol addiction (Barker, 2025). Such clinical benefits have been increasingly associated with neuroplastogenic and psychoplastogenic effects, which cause direct binding to serotonin 5-HT2A receptors, sigma-1 receptors, and the brain-derived neurotrophic factor (BDNF) receptor TrkB, leading to structural changes in the brain (Barker, 2025). Modern research is largely dedicated to creating nonhallucinogenic analogs of the LSD D-ring in order to foster effective harm-reduction strategies and avoid the unpredictable complications and side effects, along with the high monitoring costs, of a full subjective hallucinogenic experience (Barker, 2025).

Before the Drug Abuse Control Amendments of 1965, there was already research being done into potential therapeutic uses of psilocybin starting around 1960 (LeCompte, 2022). Presently, there is evidence regarding the therapeutic potential for psilocybin. It has been found to greatly improve mood and social connectedness in people who participate in psilocybin-assisted group therapy. In one study, many participants reported being able to process their trauma “experientially,” a mode of processing allowing them to feel and release the emotions that they had subconsciously been burying (Agin-Liebes et al., 2024). These effects are promising as a treatment for symptoms of anxiety, depression, post-traumatic stress disorder, and many other disorders, though the effectiveness is unclear, as this data is still very new and experimental (Irrmischer et al., 2026).

LSD has long been the subject of intense social, political, and clinical controversy in both the public and scientific views. During the 1950s and early 1960s, LSD was considered to be a very promising innovation in psychiatry, and its therapeutic potential was reported in the treatment of alcoholism and neurosis, while producing more than 1,000 scientific papers from pioneering researchers such as Humphry Osmond and Ronald Sandison (Costandi, 2014). In the mid-1960s, however, the compound moved from controlled clinical trials to the streets, and its use was massively stigmatized and was linked to the student riots, the anti-war movement, and the counterculture movement (Costandi, 2014). As a result, in 1968, the U.S. federal government banned LSD, enacting strict legislation that stunted this important research for decades, even though initial results were promising (Costandi, 2014). This political response turned the tide from a medical miracle to a drug of abuse, although in recent times, newfound scientific interest has made it easier to rethink its use for life-threatening anxiety and psychiatric conditions (Costandi, 2014).

It is a common misconception that psychedelics, including psilocybin, are dangerous, addictive chemicals only used in party settings. This is a misconception for a few reasons. One is that psilocybin has a relatively low risk of addiction. Also, in a controlled environment with professionals, it has shown promising signs of being useful in therapy settings. However, any chemical can be dangerous when used incorrectly or in ways it is not approved to be used (Pearl Psychedelic Institute, 2025).

• Agin-Liebes, G., Ekman, E., Anderson, B., Malloy, M., Haas, A., & Woolley, J. (2024). Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: An interpretive phenomenological analysis. Journal of Humanistic Psychology, 64(4), 564–591.
• Barker, S. A. (2025). Simple analogs of the LSD d-ring: A consideration of structure-activity relationships and their potential as therapeutics. ACS Chemical Neuroscience, 16(21), 4309–4314.
• Bedford, P., Hauke, D. J., Wang, Z., et al. (2023). The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity. Neuropsychopharmacology, 48(8), 1175–1183.
• Costandi, M. (2014, September 2). A brief history of psychedelic psychiatry. The Guardian.
• Das, S., Barnwal, P., Ramasamy, A., Sen, S., & Mondal, S. (2016). Lysergic acid diethylamide: A drug of 'use'? Therapeutic Advances in Psychopharmacology, 6(3), 214–228.
• de la Fuente Revenga, M., Jaster, A. M., McGinn, J., Silva, G., Saha, S., & González-Maeso, J. (2022). Tolerance and cross-tolerance among psychedelic and nonpsychedelic 5-HT2A receptor agonists in mice. ACS Chemical Neuroscience, 13(16), 2436–2448.
• Hart, C. L., & Ksir, C. (2022). Drugs, society & human behavior (18th ed.). McGraw-Hill Education.
• Irrmischer, M., Aqil, M., Luan, L., Wang, T., Engelbregt, H., Carhart-Harris, R., ... & Timmermann, C. (2026). DMT-induced shifts in criticality correlate with self-dissolution. The Journal of Neuroscience, 46(2), e0344252025.
• Krebs, T. S., & Johansen, P. Ø. (2013). Over 30 million psychedelic users in the United States. F1000Research, 2, 98.
• LeCompte, Z. (2022). Not groovy man: Psilocybin's long and complicated history with the law, and its potential to treat the growing mental health crisis in America. University of Cincinnati Law Review, 90(4), 1113–1171.
• Li, H., Zhong, Y., Yang, S., Wang, J., Li, X., Xu, J., Gao, H., & Chen, G. (2022). The potential role of lysergic acid diethylamide for psychological assisted therapy: A meta-analysis of randomised controlled trials in healthy volunteers. Human Psychopharmacology, 37(3), e2825.
• Pearl Psychedelic Institute. (2025, April 25). Breaking stigmas: Addressing common misconceptions about psychedelic assisted therapy. Pearl.
• Psilocybin (magic mushrooms). Alcohol and Drug Foundation. (2025, March 6).
• Smausz, R., Neill, J., & Gigg, J. (2022). Neural mechanisms underlying psilocybin's therapeutic potential – the need for preclinical in vivo electrophysiology. Journal of Psychopharmacology, 36(7), 781–793.
• Subramanian, S., Reneau, T. R., Perry, D., Chacko, R., Laumann, T. O., Flavin, K., Horan, C., Schweiger, J., Metcalf, N., Lenze, E. J., Snyder, A. Z., Dosenbach, N. U. F., Nicol, G., & Siegel, J. S. (2025). Psilocybin's acute and persistent brain effects: A precision imaging drug trial. Scientific Data, 12(1), 941.